NCT03518047 - Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2018

Primary Completion Date

February 11, 2020

Study Completion Date

February 11, 2020

Conditions

Psoriasis

Interventions

DRUG

risankizumab

rizankizumab subcutaneous (SC) infusion

DRUG

placebo for rizankizumab

placebo for rizankizumab subcutaneous (SC) infusion

Trial Locations (6)

Family Outpatient clinic#4 LLC /ID# 207441, Korolev

SBHI KVD # 10 Clinic of Dermatology and venerology /ID# 200615, Saint Petersburg

LLC ArsVitae Severo-Zapad /ID# 200658, Saint Petersburg

LLC Kurator /ID# 200616, Saint Petersburg

GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 201713, Krasnodar

Alliance Biomedical Ural Group /ID# 201681, Izhevsk